These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24195772)

  • 1. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
    Marcinak J; Cao C; Lee D; Ye Z
    Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2016 Sep; 18(9):925-9. PubMed ID: 27178047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
    Lee RD; Nudurupati S; Marcinak J; Viswanathan P
    Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
    Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
    Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.
    Kaku K; Araki T; Yoshinaka R
    Diabetes Care; 2013 Feb; 36(2):245-50. PubMed ID: 23086138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.
    Marcinak J; Vakilynejad M; Kogame A; Tagawa Y
    Drugs R D; 2018 Jun; 18(2):109-118. PubMed ID: 29488154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].
    Tsujihata Y
    Nihon Yakurigaku Zasshi; 2014 Aug; 144(2):59-63. PubMed ID: 25109517
    [No Abstract]   [Full Text] [Related]  

  • 16. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans.
    Kogame A; Lee R; Pan L; Sudo M; Nonaka M; Moriya Y; Higuchi T; Tagawa Y
    Xenobiotica; 2019 Apr; 49(4):433-445. PubMed ID: 29557709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function.
    Mayer M; Nudurupati S; Peng X; Marcinak J
    Drugs R D; 2014 Dec; 14(4):273-82. PubMed ID: 25374042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
    Menon V; Lincoff AM; Nicholls SJ; Jasper S; Wolski K; McGuire DK; Mehta CR; Rosenstock J; Lopez C; Marcinak J; Cao C; Nissen SE;
    Diabetes Care; 2018 Dec; 41(12):2603-2609. PubMed ID: 30459247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
    Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
    J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
    Burant CF; Viswanathan P; Marcinak J; Cao C; Vakilynejad M; Xie B; Leifke E
    Lancet; 2012 Apr; 379(9824):1403-11. PubMed ID: 22374408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.